These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 24706775)

  • 1. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Cillo AR; Sobolewski MD; Bosch RJ; Fyne E; Piatak M; Coffin JM; Mellors JW
    Proc Natl Acad Sci U S A; 2014 May; 111(19):7078-83. PubMed ID: 24706775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Archin NM; Liberty AL; Kashuba AD; Choudhary SK; Kuruc JD; Crooks AM; Parker DC; Anderson EM; Kearney MF; Strain MC; Richman DD; Hudgens MG; Bosch RJ; Coffin JM; Eron JJ; Hazuda DJ; Margolis DM
    Nature; 2012 Jul; 487(7408):482-5. PubMed ID: 22837004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
    Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
    Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
    Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
    J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
    PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
    Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
    Wei DG; Chiang V; Fyne E; Balakrishnan M; Barnes T; Graupe M; Hesselgesser J; Irrinki A; Murry JP; Stepan G; Stray KM; Tsai A; Yu H; Spindler J; Kearney M; Spina CA; McMahon D; Lalezari J; Sloan D; Mellors J; Geleziunas R; Cihlar T
    PLoS Pathog; 2014 Apr; 10(4):e1004071. PubMed ID: 24722454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency.
    Zerbato JM; Khoury G; Zhao W; Gartner MJ; Pascoe RD; Rhodes A; Dantanarayana A; Gooey M; Anderson J; Bacchetti P; Deeks SG; McMahon J; Roche M; Rasmussen TA; Purcell DF; Lewin SR
    EBioMedicine; 2021 Mar; 65():103241. PubMed ID: 33647768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effector memory differentiation increases detection of replication-competent HIV-l in resting CD4+ T cells from virally suppressed individuals.
    Wonderlich ER; Subramanian K; Cox B; Wiegand A; Lackman-Smith C; Bale MJ; Stone M; Hoh R; Kearney MF; Maldarelli F; Deeks SG; Busch MP; Ptak RG; Kulpa DA
    PLoS Pathog; 2019 Oct; 15(10):e1008074. PubMed ID: 31609991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals.
    Ho YC; Laird GM; Siliciano RF
    Proc Natl Acad Sci U S A; 2014 May; 111(19):6860-1. PubMed ID: 24799684
    [No Abstract]   [Full Text] [Related]  

  • 15. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
    Garrido C; Abad-Fernandez M; Tuyishime M; Pollara JJ; Ferrari G; Soriano-Sarabia N; Margolis DM
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.
    Del Prete GQ; Shoemaker R; Oswald K; Lara A; Trubey CM; Fast R; Schneider DK; Kiser R; Coalter V; Wiles A; Wiles R; Freemire B; Keele BF; Estes JD; Quiñones OA; Smedley J; Macallister R; Sanchez RI; Wai JS; Tan CM; Alvord WG; Hazuda DJ; Piatak M; Lifson JD
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6790-806. PubMed ID: 25182644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.
    Suryawanshi P; Bagul R; Shete A; Thakar M
    Front Immunol; 2021; 12():663919. PubMed ID: 33995393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short communication: SAHA (vorinostat) induces CDK9 Thr-186 (T-loop) phosphorylation in resting CD4+ T cells: implications for reactivation of latent HIV.
    Ramakrishnan R; Liu H; Rice AP
    AIDS Res Hum Retroviruses; 2015 Jan; 31(1):137-41. PubMed ID: 24528253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
    Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
    mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIWIL4 Maintains HIV-1 Latency by Enforcing Epigenetically Suppressive Modifications on the 5' Long Terminal Repeat.
    He Z; Jing S; Yang T; Chen J; Huang F; Zhang W; Peng Z; Liu B; Ma X; Wu L; Pan T; Zhang X; Li L; Cai W; Tang X; Zhang J; Zhang H
    J Virol; 2020 May; 94(10):. PubMed ID: 32161174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.